EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Updates on Antibody Drug Conjugates and Bispecific T-Cell Engagers in SCLC

Kinsley Wang, Kyle Taing, Robert Hsu iD

Antibodies · 04.01.2026 · 15 (1) · 4

DOI: 10.3390/antib15010004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibodies, online erschienen am 04.01.2026. Verfasst von Kinsley Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, University of Arizona College of Medicine-Phoenix, Phoenix, AZ 85004, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Small-cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy characterized by rapid proliferation, early metastasis, and near-universal relapse after initial therapy. While chemo-immunotherapy modestly improves first-line outcomes, survival after progression remains poor and highlights the urgent need for biomarker-directed strategies.

Methods

A comprehensive literature search was conducted using major medical databases looking at key relevant studies on SCLC antibody studies. All authors reviewed the literature, assessed study quality, and interpreted the results from each study.

Results

Recent advances in antibody–drug conjugates (ADCs) and T-cell engagers (TCEs) have transformed therapeutic development by targeting antigens selectively expressed on SCLC cells, enabling more precise and potentially durable tumor control. DLL3 has emerged as the most clinically relevant target to date, with the bispecific TCE tarlatamab demonstrating meaningful and durable response, manageable cytokine-release toxicity, and ultimately achieving accelerated FDA approval for previously treated extensive-stage SCLC. Concurrently, DLL3-directed ADCs have shown variable efficacy, underscoring the importance of payload selection, linker chemistry, and antigen density. Beyond DLL3, next-generation ADCs targeting TROP2, B7-H3, and SEZ6 have reported encouraging early-phase activity, including response rates exceeding those of existing second-line cytotoxic options, though myelosuppression, interstitial lung disease, and hepatic toxicity remain key considerations.

Conclusions

Collectively, these emerging immunotherapies illustrate a shift toward antigen-specific targeting in a disease historically defined by limited therapeutic innovation. Continued optimization of antigen selection, payload and linker engineering, and biomarker-driven trial design will be critical for translating early promise into durable clinical benefit and reshaping the treatment landscape for SCLC.

Schlagwörter

Stichwörter der Autor:innen

DLL3T-cell engagerantibody drug conjugatesmall cell lung cancertarlatamab

Autor:innen und Institutionen

  • College of Medicine, University of Arizona College of Medicine-Phoenix, Phoenix, AZ 85004, USA.
  • Department of Internal Medicine, Huntington Health, Pasadena, CA 91105, USA.
  • Division of Medical Oncology, Department of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.

ORCID-Profile: Robert Hsu

Zitieren

APA

Wang, K., Taing, K., & Hsu, R. (2026). Updates on Antibody Drug Conjugates and Bispecific T-Cell Engagers in SCLC. Antibodies, 15(1), 4. https://doi.org/10.3390/antib15010004

Vancouver

Wang K, Taing K, Hsu R. Updates on Antibody Drug Conjugates and Bispecific T-Cell Engagers in SCLC. Antibodies. 2026;15(1):4. doi:10.3390/antib15010004

BibTeX
@article{Wang2026,
  author = {Wang, Kinsley and Taing, Kyle and Hsu, Robert},
  title = {Updates on Antibody Drug Conjugates and Bispecific T-Cell Engagers in SCLC},
  journal = {Antibodies},
  year = {2026},
  volume = {15},
  number = {1},
  pages = {4},
  doi = {10.3390/antib15010004}
}
Kostenlos starten →